Zivo Bioscience Secures New Loan Agreement

Ticker: ZIVOW · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1101026

Zivo Bioscience, Inc. 8-K Filing Summary
FieldDetail
CompanyZivo Bioscience, Inc. (ZIVOW)
Form Type8-K
Filed DateNov 15, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.001, $185,497, $40,331, $51,425, $277,254.38
Sentimentneutral

Sentiment: neutral

Topics: debt, financing, loan-agreement

TL;DR

Zivo just took out a new loan, adding to their debt obligations.

AI Summary

On November 12, 2024, Zivo Bioscience, Inc. entered into a material definitive agreement, specifically a loan agreement. This agreement creates a direct financial obligation for the company, indicating it has taken on new debt. The filing also includes financial statements and exhibits related to this event.

Why It Matters

This filing indicates Zivo Bioscience has taken on new debt, which could impact its financial structure and future operations.

Risk Assessment

Risk Level: medium — Taking on new debt can increase financial risk for a company, especially if its ability to repay is uncertain.

Key Players & Entities

  • Zivo Bioscience, Inc. (company) — Registrant
  • November 12, 2024 (date) — Date of earliest event reported

FAQ

What is the principal amount of the new loan agreement?

The filing does not specify the principal amount of the loan agreement.

Who is the lender in this new loan agreement?

The filing does not disclose the identity of the lender.

What are the key terms and conditions of the loan agreement?

The filing mentions the entry into a material definitive agreement and a direct financial obligation but does not detail the specific terms and conditions.

What is the purpose of this new loan?

The purpose of the loan is not explicitly stated in the provided filing excerpt.

Are there any specific covenants or restrictions associated with this loan?

The filing does not provide details on any covenants or restrictions related to the loan.

Filing Stats: 773 words · 3 min read · ~3 pages · Grade level 10.1 · Accepted 2024-11-15 06:30:49

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share ZIVO OTCQB Warrants to p
  • $185,497 — Pension Fund in the principal amount of $185,497.12, $40,331.51, and $51,425.75, respect
  • $40,331 — in the principal amount of $185,497.12, $40,331.51, and $51,425.75, respectively. The N
  • $51,425 — amount of $185,497.12, $40,331.51, and $51,425.75, respectively. The Notes have an agg
  • $277,254.38 — s have an aggregate principal amount of $277,254.38. Each Note is payable in 24 equal mont

Filing Documents

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant On November 12, 2024, Zivo Bioscience, Inc. (the"Company") entered into a Debt Settlement Agreement ("Debt Settlement Agreement") with each of Howard Shapiro, Merger Masters Pension Fund, and Financial Trading Consultants Pension Fund (each a"Creditor") to restructure certain debt of the Company. Each Creditor agreed to settle the Company's existing debt in exchange for the Company issuing each Creditor an unsecured promissory note (each a"Note,"collectively, the"Notes") pursuant to the terms agreed upon in each Debt Settlement Agreement. The Company issued a Note to each of Howard Shapiro, Merger Masters Pension Fund, and Financial Trading Consultants Pension Fund in the principal amount of $185,497.12, $40,331.51, and $51,425.75, respectively. The Notes have an aggregate principal amount of $277,254.38. Each Note is payable in 24 equal monthly installments beginning November 30, 2024 and bears interest at a rate of 1.0% per annum. Each Note is subject to customary events of default, the occurrence of which will trigger, at the option of the respective Creditor, the unpaid principal balance of the Note becoming immediately due and payable. The principal balance may be prepaid at any time without penalty. A copy of each Debt Settlement Agreement is attached as Exhibits 10.1, 10.2, 10.3, and each Note is attached as Exhibits 10.4, 10.5, and 10.6, to this Current Report on Form 8-K and is incorporated herein by reference. The disclosure set forth in this Item 2.03 is intended to be a summary only and is qualified in its entirety by reference to each Debt Settlement Agreement and Note.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Debt Settlement Agreement, dated November 12, 2024, by and between Howard Shapiro and the Company 10.2 Debt Settlement Agreement, dated November 12, 2024, by and between Merger Masters Pension Fund and the Company 10.3 Debt Settlement Agreement, dated November 12, 2024, by and between Financial Trading Consultants Pension Fund and the Company 10.4 Promissory Note, dated November 12, 2024, in favor of Howard Shapiro 10.5 Promissory Note, dated November 12, 2024, in favor of Merger Masters Pension Fund 10.6 Promissory Note, dated November 12, 2024, in favor of Financial Trading Consultants Pension Fund 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZIVO BIOSCIENCE, INC. By: /s/ Keith Marchiando Keith Marchiando Chief Financial Officer Date: November 15, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.